研究单位：[1]Sun Yat-sen University[2]Akeso Pharmaceuticals, Inc.[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China,233000[4]The First Affiliated Hospital of University of Science and Technology of China,Hefei,Anhui,China,230041[5]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China[6]Fujian Cancer Hospital,Fuzhou,Fujian,China[7]Dongguan Peaple's Hospital,Dongguan,Guangdong,China[8]Sun Yat-sen Memorial Hospital,Guangzhou,Guangdong,China,510000[9]SUN YAT-SEN UNIVERSITY cANCER CENTER,Guangzhou,Guangdong,China,510060[10]Shenzhen People's Hospital,Shenzhen,Guangdong,China,518001[11]Zhongshan city Peaple's Hospital,Zhongshan,Guangdong,China[12]Cancer Hospital of Guangxi Medical University,Nanning,Guangxi,China[13]Cancer Hospital of Guizhou Medical University,Guiyang,Guizhou,China[14]Renmin Hospital of Wuhan University,Wuhan,Hubei,China,430000[15]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China,430071[16]Hubei Province Cancer Hosiptal,Wuhan,Hubei,China[17]Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China[18]Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China[19]Hunan Cancer Hospital,Changsha,Hunan,China,410000[20]Xiangya Hospital Central South University,Changsha,Hunan,China
The trial aimed to compare cadonilimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in high-risk locoregionally-advanced nasopharyngeal carcinoma (LANPC).
